GeoVax Highlights Need for Domestic MVA Vaccine Infrastructure Amid Global Outbreaks
As WHO declares Ebola a public health emergency and mpox spreads, GeoVax emphasizes the strategic importance of scalable U.S.-based MVA manufacturing for biodefense.
Amid escalating global infectious disease threats, including the World Health Organization's declaration of a Public Health Emergency of International Concern (PHEIC) for an Ebola outbreak involving the Bundibugyo strain, GeoVax Labs (Nasdaq: GOVX) is underscoring the need for diversified vaccine supply and scalable domestic manufacturing capabilities. The clinical-stage biotechnology company, which is developing a Modified Vaccinia Ankara (MVA)-based vaccine for mpox and smallpox, argues that recent events highlight the importance of a robust, flexible preparedness infrastructure.
GeoVax's CEO David A. Dodd stated, "These developments reinforce the importance of scalable and flexible vaccine preparedness infrastructure." The company's primary focus is advancing GEO-MVA, its MVA-based mpox and smallpox vaccine candidate, which recently received positive Scientific Advice from the European Medicines Agency supporting a Phase 3 immunobridging pathway. The pivotal trial is scheduled to start in Q4 2026, with data expected by mid-2027.
GeoVax believes that the ongoing international spread of Clade I mpox and recent hantavirus concerns further emphasize the strategic importance of diversified vaccine supply infrastructure, scalable domestic manufacturing, rapid-response platform technologies, and long-term biodefense investment. The company also noted that its MVA platform has demonstrated broad applicability, including prior preclinical studies where an MVA-based Ebola-Zaire vaccine provided complete protection in non-human primates.
"Recent events continue to demonstrate that preparedness infrastructure cannot remain reactive or narrowly focused on individual outbreak cycles," said Dodd. "We believe the advancement of scalable domestic MVA-based manufacturing capability represents an important strategic objective for strengthening future biodefense readiness."
GeoVax's GEO-MVA program aims to support global orthopoxvirus preparedness and address the need for expanded vaccine supply. The company is also developing other pipeline candidates, including Gedeptin for cancer and GEO-CM04S1 for COVID-19. For more information, visit www.geovax.com.